Kazia Therapeutics Ltd
KZIA9.790USD
0.000
Handelsschluss 06/13, 16:00（ET）Kurse um 15 Minuten verzögert
32.59MMarktkapitalisierung
--KGV TTM
mehr Informationen über Kazia Therapeutics Ltd Unternehmen
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Unternehmensinformationen
BörsenkürzelKZIA
Name des UnternehmensKazia Therapeutics Ltd
IPO-datumSep 01, 1994
Gegründet am1994
CEODr. John E. Friend, M.D.
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeSep 01
AddresseThree International Towers Level 24,
StadtSYDNEY
BörseNASDAQ Capital Market Consolidated
LandAustralia
Postleitzahl2000
Telefon1161298780088
Websitehttps://www.kaziatherapeutics.com/
BörsenkürzelKZIA
IPO-datumSep 01, 1994
Gegründet am1994
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Mar 4
Währung: USDAktualisiert: Tue, Mar 4
FY2022
FY2021
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Sweden (Country)
0.00
0.00%
China (Country)
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: 13 hours ago
Aktualisiert: 13 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Chernett (Jorey)
10.09%
Barclays Capital Inc.
1.77%
UBS Financial Services, Inc.
0.39%
MAI Capital Management, LLC
0.06%
Rhumbline Advisers Ltd. Partnership
0.03%
Other
87.67%
Aktionäre
Aktionäre
Anteil
Chernett (Jorey)
10.09%
Barclays Capital Inc.
1.77%
UBS Financial Services, Inc.
0.39%
MAI Capital Management, LLC
0.06%
Rhumbline Advisers Ltd. Partnership
0.03%
Other
87.67%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
10.09%
Research Firm
1.77%
Investment Advisor
0.43%
Investment Advisor/Hedge Fund
0.08%
Hedge Fund
0.02%
Other
87.62%
Institutionelle Beteiligung
Aktualisiert: Tue, Mar 4
Aktualisiert: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
38
13.88K
1.02%
-25.51K
2024Q4
39
333.53K
5.24%
-391.82K
2024Q3
37
220.02K
0.81%
-322.92K
2024Q2
32
329.65K
0.99%
-162.64K
2024Q1
33
37.63K
1.43%
-462.76K
2023Q4
33
488.86K
18.54%
+447.75K
2023Q3
33
24.22K
1.03%
-36.82K
2023Q2
34
28.95K
1.27%
-34.22K
2023Q1
33
27.66K
1.21%
-46.04K
2022Q4
36
43.17K
2.64%
-48.21K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Barclays Capital Inc.
24.00K
0.38%
+24.00K
--
Dec 31, 2024
UBS Financial Services, Inc.
5.51K
0.09%
+520.00
+10.42%
Dec 31, 2024
MAI Capital Management, LLC
27.84K
0.44%
+564.00
+2.07%
Dec 31, 2024
Rhumbline Advisers Ltd. Partnership
556.00
0.01%
--
--
Dec 31, 2024
Armistice Capital LLC
1.10K
0.02%
+1.10K
--
Sep 30, 2024
Osaic Holdings, Inc.
100.00
0%
+90.00
+900.00%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Datum
Art
Verhältnis
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
